I kliniske undersøgelser blev den daglige dosis reduceret på grund af bivirkninger hos cirka 16% af de behandlede hunde og hovedsagelig på grund af stigning i transaminaser.
During clinical studies, the daily dose was decreased due to adverse events in approximately 16% of treated dogs and mainly due to an increase in transaminases.